

## Mavis Waller Appointed to Vice President, Clinical Operations as HemoShear Readies for Clinical Trials



Mavis Waller, who joined HemoShear this January as Executive Director, has been appointed to Vice President, Clinical Operations. Mavis will provide strategic direction and oversight for the company's HST5040 clinical research program for treating rare genetic disorders methylmalonic acidemia (MMA) and propionic acidemia (PA), as well as other diseases in the future.

"Mavis and I worked together for several years when we were colleagues at PRA International (now PRA Health Sciences), and we are fortunate to have a world-class clinical research leader like her on our team," said Jim Powers, Chairman and CEO of HemoShear. "As we look to initiate our HST5040 clinical trials, Mavis will provide the operational excellence and cross functional team management required to conduct high quality and timely studies."

Mavis has decades of experience managing comprehensive clinical trial programs, having spent 21 years working at contract research organizations and 13 years at pharmaceutical companies. She joined HemoShear after spending five years as senior project director for Syneos Health, where she provided oversight to complex global research programs in gastroenterology, rare disease and vaccines. Earlier in her career she spent nine years at PRA. Mavis has a bachelor's degree from the University of Virginia.

Mavis will work closely with Gerry Cox, MD, PhD, acting Chief Medical Officer, to manage HemoShear's upcoming phase 2 clinical study, **HERO (HElP Reduce Organic acids)**. HERO is designed to enroll at least 12 patients with MMA and PA at select children's hospitals in the United States.

"I enjoy working with my colleagues at HemoShear and their unique culture," said Mavis. "I am excited to begin the HST5040 study and the prospect of bringing a meaningful treatment to patients with these serious diseases."